Novartis' SMA gene-therapy, if priced at $2M, could be more cost-effective than Biogen's Spinraza — ICER
Biogen’s Spinraza was approved by the FDA amidst much fanfare in 2016 as the first and only disease-modifying treatment for SMA, a rare and often …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
